Margarita Salcedo‐Magguilli

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

Bruno François, Simon Lambden, Tom Fivez et al. · The Lancet Respiratory Medicine · 2023 · 74 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +11

Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial

Bruno François, Xavier Wittebole, Ricard Ferrer et al. · Intensive Care Medicine · 2020 · 71 citations · Full text

Veterinary Medicine, Infectious Diseases, Inflammation +6

A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition

Valérie Cuvier, Ulrike Lorch, Stephan Witte et al. · British Journal of Clinical Pharmacology · 2018 · 44 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial

Bruno François, Simon Lambden, Sébastien Gibot et al. · BMJ Open · 2021 · 20 citations · Full text

Veterinary Medicine, Pharmacology, Pharmacotherapy +17

Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial

Bruno François, Simon Lambden, Jean–Jacques Garaud et al. · EClinicalMedicine · 2023 · 18 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15